Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × abemaciclib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 91 Neoplasm Metastasis 11 Triple Negative Breast Neoplasms 5 Neoplasms 5 Breast Diseases 4 Unilateral Breast Neoplasms 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasms by Site 2 Lymphoma, Non-Hodgkin 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Breast Cancer Female 2 Brain Neoplasms 2 Venous Thromboembolism 1 Thrombocytosis 1 Solid Tumor 1 Sarcoma 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mesothelioma, Malignant 1

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Capecitabine 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Trastuzumab 2 Gemcitabine 2 Docetaxel 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡